Analysis Flags Myriad Genetics, Guardant Health, Coherent as Cash-Burning Risks

Myriad Genetics (MYGN), Guardant Health (GH), and Coherent (COHR) face heightened scrutiny after a June 5, 2026, StockStory analysis categorized them as cash-burning companies with high-risk, high-reward profiles. Myriad Genetics, trading at $4.69 per share with a 38.4x forward P/E ratio, posted a trailing 12-month free cash flow margin of -1.6%. Guardant Health showed the steepest cash burn at -22% free cash flow margin, with its stock at $133.50 implying a 12x forward price-to-sales valuation. Coherent, priced at $411.80 and 56.1x forward P/E, burned cash at an -8.2% margin. Without a clear path to profitability, such companies risk shareholder dilution, mounting debt, or worse, the report noted. The analysis singled out MYGN as the sole name with “promising prospects” amid the group, while urging caution on GH and COHR.